S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

Ekso Bionics (EKSO) Stock Forecast, Price & News

+0.03 (+1.66%)
(As of 05/27/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
20,377 shs
Average Volume
50,105 shs
Market Capitalization
$23.63 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive EKSO News and Ratings via Email

Sign-up to receive the latest news and ratings for Ekso Bionics and its competitors with MarketBeat's FREE daily newsletter.

Ekso Bionics logo

About Ekso Bionics

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.


See More Headlines

Industry, Sector and Symbol

General industrial machinery,
Current Symbol
Previous Symbol
Year Founded

Sales & Book Value

Annual Sales
$11.25 million
Book Value
$2.61 per share


Net Income
$-9.76 million
Pretax Margin




Free Float
Market Cap
$23.63 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.02 out of 5 stars

Medical Sector

571st out of 1,424 stocks

General Industrial Machinery, Industry

4th out of 13 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -

Ekso Bionics (NASDAQ:EKSO) Frequently Asked Questions

Is Ekso Bionics a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Ekso Bionics stock.
View analyst ratings for Ekso Bionics
or view top-rated stocks.

When is Ekso Bionics' next earnings date?

Ekso Bionics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Ekso Bionics

How were Ekso Bionics' earnings last quarter?

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) issued its earnings results on Thursday, April, 28th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.05. Ekso Bionics had a negative trailing twelve-month return on equity of 33.87% and a negative net margin of 90.01%. During the same period in the previous year, the firm earned ($0.34) earnings per share.
View Ekso Bionics' earnings history

When did Ekso Bionics' stock split? How did Ekso Bionics' stock split work?

Shares of Ekso Bionics reverse split on Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 4th 2016. An investor that had 100 shares of Ekso Bionics stock prior to the reverse split would have 14 shares after the split.

What price target have analysts set for EKSO?

1 brokerages have issued 12 month target prices for Ekso Bionics' shares. Their forecasts range from $11.00 to $11.00. On average, they anticipate Ekso Bionics' share price to reach $11.00 in the next twelve months. This suggests a possible upside of 497.8% from the stock's current price.
View analysts' price targets for Ekso Bionics
or view top-rated stocks among Wall Street analysts.

Who are Ekso Bionics' key executives?
Ekso Bionics' management team includes the following people:
  • Mr. Steven A. Sherman, Chairman & CEO (Age 76, Pay $100k)
  • Mr. John F. Glenn, CFO & Sec. (Age 60, Pay $332k)
  • Mr. William R. Shaw, Consultant (Age 47, Pay $402.14k)
  • Mr. Scott W. Davis, Pres & COO
  • Ms. Rachael Anderson, Global Director of Marketing & Strategic Growth
  • Mr. Anthony Pratt, US Director of Sales
  • Ms. Foon Lim Chwee, Pres of APAC
  • Mr. Jerome Wong, Corp. Controller
What other stocks do shareholders of Ekso Bionics own?
What is Ekso Bionics' stock symbol?

Ekso Bionics trades on the NASDAQ under the ticker symbol "EKSO."

Who are Ekso Bionics' major shareholders?

Ekso Bionics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.43%), Essex Investment Management Co. LLC (1.31%), Renaissance Technologies LLC (0.14%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Ekso Bionics stock include Jason C Jones, John Glenn, Scott G Davis and Steven Sherman.
View institutional ownership trends for Ekso Bionics

Which major investors are selling Ekso Bionics stock?

EKSO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc., and Simplex Trading LLC. Company insiders that have sold Ekso Bionics company stock in the last year include Jason C Jones, John Glenn, Scott G Davis, and Steven Sherman.
View insider buying and selling activity for Ekso Bionics
or view top insider-selling stocks.

Which major investors are buying Ekso Bionics stock?

EKSO stock was bought by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC.
View insider buying and selling activity for Ekso Bionics
or or view top insider-buying stocks.

How do I buy shares of Ekso Bionics?

Shares of EKSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ekso Bionics' stock price today?

One share of EKSO stock can currently be purchased for approximately $1.84.

How much money does Ekso Bionics make?

Ekso Bionics has a market capitalization of $23.63 million and generates $11.25 million in revenue each year. The company earns $-9.76 million in net income (profit) each year or ($0.870010) on an earnings per share basis.

How many employees does Ekso Bionics have?

Ekso Bionics employs 55 workers across the globe.

What is Ekso Bionics' official website?

The official website for Ekso Bionics is www.eksobionics.com.

How can I contact Ekso Bionics?

Ekso Bionics' mailing address is 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804. The company can be reached via phone at (510) 984-1761, via email at [email protected], or via fax at 510-927-2647.

This page was last updated on 5/28/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.